Innoviva (INVA) Competitors

$22.52 -0.38 (-1.64%)

Closing price 03:59 PM Eastern

Extended Trading

$22.52 +0.01 (+0.04%)

As of 04:04 PM Eastern

INVA vs. RGEN, ALKS, LGND, FOLD, and BCRX

Should you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include Repligen (RGEN), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "biotechnology" industry.

How does Innoviva compare to Repligen?

Repligen (NASDAQ:RGEN) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

In the previous week, Repligen had 11 more articles in the media than Innoviva. MarketBeat recorded 19 mentions for Repligen and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.17 beat Repligen's score of 0.40 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	3 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a net margin of 119.89% compared to Repligen's net margin of 6.73%. Innoviva's return on equity of 33.33% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.73%	4.88%	3.48%
Innoviva	119.89%	33.33%	22.67%

97.6% of Repligen shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 0.6% of Repligen shares are held by company insiders. Comparatively, 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Repligen currently has a consensus target price of $169.62, indicating a potential upside of 46.39%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 60.78%. Given Innoviva's higher possible upside, analysts plainly believe Innoviva is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has lower revenue, but higher earnings than Repligen. Innoviva is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	8.85	$48.89M	$0.90	128.74
Innoviva	$411.33M	4.05	$271.17M	$6.01	3.75

Repligen has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.

Summary

Innoviva beats Repligen on 9 of the 17 factors compared between the two stocks.

How does Innoviva compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 2.0% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Innoviva has lower revenue, but higher earnings than Alkermes. Innoviva is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.01	$241.66M	$0.90	39.46
Innoviva	$411.33M	4.05	$271.17M	$6.01	3.75

Innoviva has a net margin of 119.89% compared to Alkermes' net margin of 9.78%. Innoviva's return on equity of 33.33% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Innoviva	119.89%	33.33%	22.67%

Alkermes has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Alkermes presently has a consensus target price of $45.21, indicating a potential upside of 27.31%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 60.78%. Given Innoviva's higher probable upside, analysts plainly believe Innoviva is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.82
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Alkermes had 16 more articles in the media than Innoviva. MarketBeat recorded 24 mentions for Alkermes and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.17 beat Alkermes' score of 0.65 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	8 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats Alkermes on 10 of the 17 factors compared between the two stocks.

How does Innoviva compare to Ligand Pharmaceuticals?

Innoviva (NASDAQ:INVA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Ligand Pharmaceuticals had 13 more articles in the media than Innoviva. MarketBeat recorded 21 mentions for Ligand Pharmaceuticals and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.17 beat Ligand Pharmaceuticals' score of 0.43 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innoviva has higher revenue and earnings than Ligand Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.05	$271.17M	$6.01	3.75
Ligand Pharmaceuticals	$268.09M	16.48	$124.45M	$7.37	29.91

Innoviva has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Innoviva presently has a consensus target price of $36.20, suggesting a potential upside of 60.78%. Ligand Pharmaceuticals has a consensus target price of $257.71, suggesting a potential upside of 16.90%. Given Innoviva's higher possible upside, equities research analysts clearly believe Innoviva is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Innoviva has a net margin of 119.89% compared to Ligand Pharmaceuticals' net margin of 55.95%. Innoviva's return on equity of 33.33% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

99.1% of Innoviva shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Innoviva and Ligand Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Innoviva compare to Amicus Therapeutics?

Innoviva (NASDAQ:INVA) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Innoviva currently has a consensus price target of $36.20, indicating a potential upside of 60.78%. Amicus Therapeutics has a consensus price target of $14.56, indicating a potential upside of 0.50%. Given Innoviva's stronger consensus rating and higher possible upside, research analysts clearly believe Innoviva is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Amicus Therapeutics	1 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.08

Innoviva has a net margin of 119.89% compared to Amicus Therapeutics' net margin of -4.27%. Innoviva's return on equity of 33.33% beat Amicus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Amicus Therapeutics	-4.27%	4.15%	1.09%

Innoviva has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.05	$271.17M	$6.01	3.75
Amicus Therapeutics	$634.21M	7.17	-$27.11M	-$0.08	N/A

Innoviva has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

In the previous week, Innoviva had 7 more articles in the media than Amicus Therapeutics. MarketBeat recorded 8 mentions for Innoviva and 1 mentions for Amicus Therapeutics. Innoviva's average media sentiment score of 1.17 beat Amicus Therapeutics' score of 1.11 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amicus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Innoviva shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Innoviva beats Amicus Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Innoviva compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

BioCryst Pharmaceuticals presently has a consensus target price of $20.70, suggesting a potential upside of 141.15%. Innoviva has a consensus target price of $36.20, suggesting a potential upside of 60.78%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe BioCryst Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.

Innoviva has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$885.72M	2.46	$263.86M	-$1.78	N/A
Innoviva	$411.33M	4.05	$271.17M	$6.01	3.75

Innoviva has a net margin of 119.89% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Innoviva's return on equity of 33.33% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Innoviva	119.89%	33.33%	22.67%

In the previous week, BioCryst Pharmaceuticals had 14 more articles in the media than Innoviva. MarketBeat recorded 22 mentions for BioCryst Pharmaceuticals and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.17 beat BioCryst Pharmaceuticals' score of 0.04 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

BioCryst Pharmaceuticals and Innoviva tied by winning 8 of the 16 factors compared between the two stocks.

Get Innoviva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INVA vs. The Competition

Export

Metric	Innoviva	Large Cap Pharma Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.67B	$289.19B	$6.18B	$12.27B
Dividend Yield	N/A	2.83%	2.78%	5.22%
P/E Ratio	3.75	25.83	20.66	25.69
Price / Sales	4.05	4.76	527.03	64.81
Price / Cash	4.55	12.33	27.81	36.27
Price / Book	1.43	7.28	9.77	6.74
Net Income	$271.17M	$11.61B	$3.54B	$333.09M
7 Day Performance	N/A	N/A	N/A	0.52%
1 Month Performance	-5.24%	-1.91%	6.33%	9.09%
1 Year Performance	21.31%	22.86%	41.88%	42.54%

Innoviva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INVA Innoviva	3.4989 of 5 stars	$22.52 -1.6%	$36.20 +60.8%	+23.3%	$1.67B	$411.33M	3.75	100	Positive News Earnings Report Analyst Downgrade
RGEN Repligen	3.8194 of 5 stars	$117.20 -0.9%	$170.25 +45.3%	+0.2%	$6.61B	$738.26M	137.88	2,000	Earnings Report
ALKS Alkermes	3.2758 of 5 stars	$33.38 -1.0%	$44.29 +32.7%	+16.1%	$5.55B	$1.48B	23.34	2,050
LGND Ligand Pharmaceuticals	4.0571 of 5 stars	$227.44 -0.9%	$256.29 +12.7%	+111.9%	$4.56B	$268.09M	39.01	80	Earnings Report Upcoming Earnings Analyst Forecast
FOLD Amicus Therapeutics	1.0945 of 5 stars	$14.49 flat	$14.56 +0.5%	+142.3%	$4.55B	$634.21M	N/A	480	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INVA) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innoviva (INVA) Competitors

INVA vs. RGEN, ALKS, LGND, FOLD, and BCRX

How does Innoviva compare to Repligen?

Summary

How does Innoviva compare to Alkermes?

Summary

How does Innoviva compare to Ligand Pharmaceuticals?

Summary

How does Innoviva compare to Amicus Therapeutics?

Summary

How does Innoviva compare to BioCryst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innoviva (INVA) Competitors

INVA vs. RGEN, ALKS, LGND, FOLD, and BCRX

How does Innoviva compare to Repligen?

Does the media prefer RGEN or INVA?

Is RGEN or INVA more profitable?

Do insiders and institutionals believe in RGEN or INVA?

Do analysts prefer RGEN or INVA?

Which has better valuation and earnings, RGEN or INVA?

Which has more volatility and risk, RGEN or INVA?

Summary

How does Innoviva compare to Alkermes?

Do institutionals & insiders believe in ALKS or INVA?

Which has better earnings and valuation, ALKS or INVA?

Is ALKS or INVA more profitable?

Which has more volatility & risk, ALKS or INVA?

Do analysts prefer ALKS or INVA?

Does the media favor ALKS or INVA?

Summary

How does Innoviva compare to Ligand Pharmaceuticals?

Does the media prefer INVA or LGND?

Which has better earnings & valuation, INVA or LGND?

Which has more risk and volatility, INVA or LGND?

Do analysts rate INVA or LGND?

Is INVA or LGND more profitable?

Do institutionals & insiders hold more shares of INVA or LGND?

Summary

How does Innoviva compare to Amicus Therapeutics?

Do analysts prefer INVA or FOLD?

Is INVA or FOLD more profitable?

Which has preferable valuation & earnings, INVA or FOLD?

Which has more volatility & risk, INVA or FOLD?

Does the media refer more to INVA or FOLD?

Do institutionals and insiders believe in INVA or FOLD?

Summary

How does Innoviva compare to BioCryst Pharmaceuticals?

Do analysts rate BCRX or INVA?

Which has more risk & volatility, BCRX or INVA?

Which has stronger valuation & earnings, BCRX or INVA?

Is BCRX or INVA more profitable?

Does the media refer more to BCRX or INVA?

Do institutionals and insiders hold more shares of BCRX or INVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools